Can FUJIFILM’s Madison facility help solve the scale problem in stem cell manufacturing?
iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.
Is iECURE’s infant gene editing therapy quietly changing the OTC deficiency playbook?
A rare disease gene editing signal is only the start. iECURE now has to prove ECUR-506 can sustain OTC deficiency control.
Could Entos Pharmaceuticals’ Fusogenix platform open a real path to treatment in L-CMD?
Entos Pharmaceuticals and the L-CMD Research Foundation are targeting a curative L-CMD therapy. Read what this could change for rare disease treatment.
Why YolTech Therapeutics’ YOLT-202 data matters for the future of gene editing in Alpha-1 Antitrypsin Deficiency
Early YOLT-202 data from YolTech Therapeutics suggests gene editing could redefine Alpha-1 Antitrypsin Deficiency treatment. Read the analysis.
What Hera BioLabs’ absorption into Demeetra reveals about IP bottlenecks in gene editing R&D
Demeetra’s acquisition of Hera BioLabs consolidates Super piggyBac IP. Find out how this could reshape gene therapy tools and licensing frameworks.
Why Aurora Therapeutics believes the FDA is ready for grouped CRISPR approvals
Can Aurora Therapeutics make CRISPR work at scale? Find out how its platform model for rare disease editing is testing biotech’s next big leap.